Synopsis
Synopsis
0
USDMF
 
																							0
CEP/COS
 
																							0
JDMF
 
																							0
EU WC
 
																							0
KDMF
 
																							0
NDC API
 
																							0
VMF
 
																							0
EDQM
0
USP
0
JP
0
Others
0
South Africa
 
																							0
Listed Dossiers
 
																							
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Weekly News Recap #Phispers


| Molecular Weight | 763.0 g/mol | 
|---|---|
| Molecular Formula | C42H66O12 | 
| XLogP3 | 5.1 | 
| Hydrogen Bond Donor Count | 7 | 
| Hydrogen Bond Acceptor Count | 12 | 
| Rotatable Bond Count | 6 | 
| Exact Mass | 762.45542754 g/mol | 
| Monoisotopic Mass | 762.45542754 g/mol | 
| Topological Polar Surface Area | 203 Ų | 
| Heavy Atom Count | 54 | 
| Formal Charge | 0 | 
| Complexity | 1530 | 
| Isotope Atom Count | 0 | 
| Defined Atom Stereocenter Count | 15 | 
| Undefined Atom Stereocenter Count | 1 | 
| Defined Bond Stereocenter Count | 0 | 
| Undefined Bond Stereocenter Count | 0 | 
| Covalently Bonded Unit Count | 1 | 
 Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
 Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is indicated for the treament of COPD with an eosinophilic phenotype.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Nucala (Mepolizumab) for Adults with COPD in The US
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is indicated for the treament of COPD with an eosinophilic phenotype.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 22, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated for the treament of COPD with an eosinophilic phenotype.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Reviews GSK’s Nucala Expansion for COPD Treatment
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated for the treament of COPD with an eosinophilic phenotype.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 24, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Nucala
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK’s Nucala Bags Another China Approval, but Biggest Test Yet to Come
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 03, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated in adults with chronic obstructive pulmonary disease (COPD).
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK's Asthma Drug Nucala Meets Main Goal in Study on Treating Smoker's Lungs
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated in adults with chronic obstructive pulmonary disease (COPD).
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 06, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
MHLW has approved Nucala (mepolizumab), a monoclonal antibody that targets IL-5, for the treatment of chronic rhinosinusitis with nasal polyps in adult patients.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Nucala
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK's Nucala Approved in Japan for Chronic Rhinosinusitis with Nasal Polyps
Details : MHLW has approved Nucala (mepolizumab), a monoclonal antibody that targets IL-5, for the treatment of chronic rhinosinusitis with nasal polyps in adult patients.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 29, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for severe eosinophilic asthma.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nucala (mepolizumab) Approved in China for Severe Asthma with Eosinophilic Phenotype Use
Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for severe eosinophilic asthma.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 10, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Mepolizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mepolizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 18, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Nucala
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK’s Regulatory Submission Accepted for Review by Japanese Regulator for Use of Nucala (Mepoliz...
Details : Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 01, 2023

Details:
Mepolizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: GSK
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2023

 
										 
										Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
The Role of IL5 in Epithelial Cell Integrity
Details : Mepolizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 09, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.
Lead Product(s): Mepolizumab,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala
Study Phase: Approved FDFProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2023

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mepolizumab,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.
Product Name : Nucala
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 14, 2023

 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
 
												 
											Patent Expiration Date : 2015-12-22
Date Granted : 2009-12-01
Brand Name : NUCALA
Patent Number : 2208503
Filing Date : 1995-12-22
Strength per Unit : 100 mg / mL
Dosage Form : POWDER FOR SOLUTION
Human Or VET : Human
Route of Administration : SUBCUTANEOUS
Patent Expiration Date : 2015-12-22
Date Granted : 2009-12-01

 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
53
PharmaCompass offers a list of Mepolizumab API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mepolizumab manufacturer or Mepolizumab supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mepolizumab manufacturer or Mepolizumab supplier.
PharmaCompass also assists you with knowing the Mepolizumab API Price utilized in the formulation of products. Mepolizumab API Price is not always fixed or binding as the Mepolizumab Price is obtained through a variety of data sources. The Mepolizumab Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mepolizumab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mepolizumab, including repackagers and relabelers. The FDA regulates Mepolizumab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mepolizumab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mepolizumab manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mepolizumab supplier is an individual or a company that provides Mepolizumab active pharmaceutical ingredient (API) or Mepolizumab finished formulations upon request. The Mepolizumab suppliers may include Mepolizumab API manufacturers, exporters, distributors and traders.
click here to find a list of Mepolizumab suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Mepolizumab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mepolizumab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mepolizumab GMP manufacturer or Mepolizumab GMP API supplier for your needs.
A Mepolizumab CoA (Certificate of Analysis) is a formal document that attests to Mepolizumab's compliance with Mepolizumab specifications and serves as a tool for batch-level quality control.
Mepolizumab CoA mostly includes findings from lab analyses of a specific batch. For each Mepolizumab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mepolizumab may be tested according to a variety of international standards, such as European Pharmacopoeia (Mepolizumab EP), Mepolizumab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mepolizumab USP).
